COMPARISON OF INSULIN LIKE GROWTH FACTOR-1 LEVELS IN CHRONIC MYELOCYTIC LEUKEMIA PATIENTS RECEIVING IMATINIB AND NILOTINIB THERAPY WITH HEALTHY POPULATIONS

Abstract

Introduction. CML is the most common form of chronic leukemia in Indonesia, whereas in Western countries it is more commonly found in the form of chronic lymphocytic leukemia (CLL). Chronic myelocytic leukemia (CML) is a chronic myeloproliferative disease with clonal abnormalities due to genetic changes in stem cell pluripotence. This disease is characterized by proliferation of granulocyte series without differentiation disorders. On the CML, the Philadelphia chromosome (Ph1 chr) is found in a reciprocal translocation 9.22 (t9; 22). Insulin-like Growth Factor-1 is a natural polypeptide in the human body that has similarities with insulin. IGF-1 plays an important role in the growth and development of tissues. As such, several studies have shown an association between IGF-1 and -2 circulation rates. IGF-1 plays an important role in terms of stimulating cell proliferation and inhibition of apoptosis. This affects the regulation of the body's physiological growth as well as pathological growth such as cancer. Until now there has been no research on IGF-1 levels in CML patients with imatinib and nilotinib treatment. Methods. This research is a cross-sectional study, by observing the status of exposure and simultaneous disease in individuals from a single population, in one period. The study was conducted in December 2019 at the Outpatient Clinic of H Adam Malik General Hospital Medan with the approval of the North Sumatera University Research Ethics Commission. Data were analyzed using SPSS where p <0.05 was considered significant. Results. This study showed that there were no differences in IGF-1 levels between CML patients who received imatinib and nilotinib therapy. The mean IGF-1 results were obtained in the imatinib group 107.43±19.70 and nilotinib 107.43±18.09. While the healthy population is 138.60±52.85. Conclusion. No significant differences were found in IGF-1 levels between CML patients receiving imatinib and nilotinib therapy with healthy populations.